{"prompt": "['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 60 of 169', 'Open-label tralokinumab arm only', 'From Week 16 through safety follow-up (FU1 [Week 66] or FU2 [Week 82]) subjects may use', 'mild to moderate strength TCS and/or TCI as needed (prn usage) on lesional skin at the', \"investigator's discretion (see Appendix 9 for TCS classification and examples). Use of TCS\", 'and TCI should be recorded as concomitant medication.', '9.8 Dose modification and IMP discontinuation rules', '9.8.1 Reasons for permanent discontinuation of IMP', 'Subjects will be permanently discontinued from IMP in the event of:', 'Anaphylactic reaction or other severe systemic reaction to IMP injection.', \"An AE that, in the opinion of the investigator or sponsor's medical expert,\", 'contraindicates further dosing.', 'Diagnosis of a malignancy during the trial, excluding carcinoma in situ of the', 'cervix, or localised squamous or basal cell carcinoma of the skin.', 'Evidence of pregnancy.', 'Any infection that is opportunistic, such as active tuberculosis and other', 'infections whose nature or course may suggest an immuno-compromised', 'status.', 'Severe laboratory abnormalities:', 'ALT and/or AST values >3x ULN with total bilirubin >2x ULN', '(unless elevated bilirubin is related to Gilbert-Meulengracht', 'Syndrome)', 'Confirmed AST and/or ALT >5x ULN (for more than 2 weeks)', 'Subjects in open-label treatment (tralokinumab 300 mg Q2W with optional use of TCS) who', 'in the opinion of the subject or investigator have unacceptable treatment effect of', 'tralokinumab may discontinue open-label treatment and enter the safety follow-up period.', 'eDoc-00631888 - Version 4.0']['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 61 of 169', '9.8.2 Reasons for temporary discontinuation of IMP', 'IMP dosing may be temporarily suspended in the event of:', 'Other intercurrent illnesses or major surgery.', 'An infection that requires parenteral treatment with antibiotic, antifungal,', 'antiviral, anti-parasitic, or anti-protozoal agents.', 'Treatment with systemic corticosteroids or non-steroidal', 'immunosuppressive/immunomodulating medications (e.g., cyclosporine,', 'methotrexate, azathioprine, mycophenolate mofetil, Janus kinase inhibitors,', 'biologic agents).', 'IMP dosing may resume after the medication leading to suspension of IMP is discontinued.', 'A decision to discontinue IMP temporarily or to reinstitute IMP treatment must be discussed', \"with sponsor's medical expert. However, the investigator may suspend trial treatment at any\", \"time, even without consultation with sponsor's medical expert if the urgency of the situation\", \"requires immediate action and if this is determined to be in the subject's best interest. In such\", \"cases, sponsor's medical expert should be informed as soon as possible.\", '9.9 Treatment logistics and accountability', '9.9.1 Labelling and packaging of IMPs', 'The IMP will be packaged in individually numbered kits, each containing 1 syringe', '(tralokinumab 150 mg or placebo).', 'Primary and secondary packaging materials (syringe and outer carton, respectively) will be', 'individually labelled.', 'The labelling of IMPs will be in accordance with Annex 13, local regulations and trial', 'requirements. Label text will be translated into local languages, as required. The inner label', 'will be in English for kits used at trial sites.', '9.9.2 Storage of IMPs', 'All LEO supplied IMPs must be stored in a secure and restricted area under the conditions', 'specified on the label and remain in the original container until dispensed.', 'eDoc-00631888 - Version 4.0']['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 62 of 169', 'The IMP must be stored at 2 to 8\u00b0C at the site. The temperature during storage must be', 'monitored by a calibrated, stationary and continuously monitoring system. Minimum', 'requirement is a calibrated min/max thermometer.', 'A temperature log must be kept to document the storage within the right temperature interval.', 'Storage facilities should be checked at least every working day.', 'Storage of IMP may be delegated, e.g. to a hospital pharmacy, as locally applicable.', 'Note that in the cases listed below, site staff should not use the affected IMP and should', 'immediately contact their CRA for further guidance:', 'Temperature excursion upon receipt or during storage at the trial site.', 'Damaged kit upon receipt.', 'Damaged syringe/cartridge.', 'Damaged IMP should be documented via IWRS (refer to the IWRS manual for further', 'details). Damaged IMP should not be used.', '9.9.3 Drug accountability', 'The investigator is fully responsible for the IMPs at the trial site and for maintaining adequate', 'control of the IMPs and for documenting all transactions with them.', 'An inventory (trial medication inventory log) must be kept of the IMP administered to each', 'subject randomised in the trial. The trial medication inventory log must be available for', 'inspection during monitoring visits and will be checked by the CRA to ensure correct', 'dispensing of the IMP.', 'Full drug accountability will also be performed in the IWRS.', 'Used syringes will be destroyed at the trial site provided the trial site has procedures in place', 'for such IMP destruction.', 'Trial sites which do not have such IMP destruction procedures in place will dispose used', 'syringes in sharps bins which will be shipped to the contract manufacturing organisation', '(CMO).', 'The trial site will maintain trial kit cartons from used kits until reconciliation. The IMP must', 'be fully accounted for by the CRA with the help of the unblinded HCP. Accountability must', 'eDoc-00631888 - Version 4.0']\n\n###\n\n", "completion": "END"}